Houlihan Lokey Advises MicroTransponder

Houlihan Lokey is pleased to announce that MicroTransponder Inc., closed an oversubscribed Series E equity financing with $73 millon led by U.S. Venture Partners (USVP), a leading healthcare venture capital firm.

MicroTransponder Inc., is a privately held, global medical device company committed to developing research-based neuroscience solutions. The company focuses on restoring independence and dignity for people suffering from neurological conditions that impair sensory and motor function. MicroTransponder's FDA-approved Vivistim® Paired VNS™ System is a first-of-its-kind, clinically proven medical technology that generates two to three times more improvement in upper limb function than rehabilitation alone for stroke survivors after six weeks of in-clinic therapy. Additionally, this is the only viable treatment option for chronic stroke patients who fail to improve arm and hand function via physical therapy. MicroTransponder was founded in 2007 and is based in Austin, Texas.

The company’s $53 million Series E funding round was led by new investor USVP. GPG Ventures and Exceller Hunt Ventures return as existing investors alongside new venture investors that include Osage University Partners, Action Potential Venture Capital, and The Vertical Group. MicroTransponder plans to use the funds to commercialize the Vivistim® Paired VNS™ System and establish it as the recommended rehabilitation intervention for stroke survivors working to improve their quality of life through more hand and arm mobility.

USVP is a leading Silicon Valley venture capital firm, partnering with entrepreneurs to transform their ideas into world-changing companies. USVP has invested in over 400 companies spanning four decades, working closely with executives and typically serving on a company’s board of directors. Together, USVP’s seasoned team combines 150 years of operating experience and investment expertise with varied backgrounds in marketing, sales, operations, finance, engineering, computing, research, and management. Companies can draw upon the firm’s deep industry expertise, technical strengths, team approach, network of outstanding individuals, and access to capital from “blue chip” limited partners, all of whom have made a positive impact on hundreds of companies. USVP assists with strategy, scaling, team building, product development, and business development.

This transaction represents Houlihan Lokey’s continued dedication and focus on capital raising and M&A in the medical technology sector. Houlihan Lokey’s Healthcare Group is among the largest dedicated healthcare investment banking groups in the world.

Houlihan Lokey served as exclusive financial advisor and placement agent to MicroTransponder.